此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

经皮(耳屏)迷走神经刺激术后房颤 (STOP_AF)

2026年8月26日 更新者:Jonathan K. Ho、University of California, Los Angeles

经皮(耳屏)迷走神经刺激(tVNS)治疗术后心房颤动(POAF)

Patients undergoing cardiac surgery are at high risk of developing atrial fibrillation (AF), with estimated rates of 30-50% and occurs at approximately 2-4 days after surgery. The autonomic nervous system is known to play a key role in AF. Animal studies have indicated that duration and inducibility of AF can be decreased with intermittent vagus nerve stimulation (VNS). In humans, literature suggests that transcutaneous (tragus) VNS (tVNS) can serve as a potentially non-invasive therapy for treatment of post-operative AF (POAF) by reducing inflammation and increasing atrial refractory period. The purpose of this study is to determine the value of tVNS in reducing the burden of POAF and days of hospitalization after cardiac surgery.

研究概览

地位

完全的

条件

详细说明

The trial will have two study arms: active tVNS vs. sham tVNS. Patients will be randomized to active tVNS vs. sham tVNS and will receive optimal post-op care in both arms. Active tVNS (Parasym device, Parasym Health, Inc, London, UK) will be performed with a clip attached to the ear at 20 hertz (Hz), 250 microseconds (ms) at a current just below discomfort threshold for one hour twice a day, starting on post-day 0. For sham tVNS, Parasym device will be attached to the ear twice a day, turned on but current set to 0 milliamp (mA), starting on post-op day 0. Stimulation will continue until 5 days post-op or discharge. Discomfort threshold will be determined in both arms pre-operatively in the conscious state. This current will be used for stimulation for this patient until they are awake and extubated after surgery. The stimulation threshold may be reassessed once the patient is able to provide feedback.

Patients will be approached and recruited prior to their scheduled cardiac surgery. Recruited patients who give informed consent will have the discomfort stimulation threshold (current that leads to discomfort at the tragus) determined prior to surgery. Post-operatively, stimulation will be performed in the tVNS group at just below discomfort threshold. In the sham group, the stimulator will be turned on but current set at 0 mA. Stimulations will be performed within 12 hours of arrival to the ICU after surgery, and then twice a day between the hours of 7:00-9:00 am and 6:00-8:00 pm. If POAF develops in either arm, stimulation will be continued for the full 5 days. Ten ml of blood will be drawn within 12 hours of arrival to the ICU after surgery and on day 3 post-op for measurement of biomarkers. Serum will be stored at -80 Celsius and processed in batches of 10-15 samples.

Sample Size:

The investigators expect cardiac surgery to be associated with 40% incidence of POAF. The investigators expect tVNS to reduce this incidence by 40%. A sample size of 133 subjects per arm will be able to achieve 80% power at alpha of 0.05. If interim analysis is planned, Pocock method will be used and a p value of 0.03 will be used for interim and 0.03 for final analysis. Data will be analyzed according to the intention-to-treat principle.

Randomization:

A 1:1 randomization ratio for the tVNS vs. sham will be utilized. Patients who meet all of the inclusion and none of the exclusion criteria will be randomized in the order of their enrollment. After completing the Informed Consent process, the subject is then randomized following completion of the baseline and demographics information case report forms. Randomization should occur prior to any study-related tests or procedures. The subjects will be considered enrolled in the study once randomization has occurred.

Randomization will be stratified by clinical center and post-operative amiodarone use. A computer-generated randomization list with random permuted block of a variable will be produced for each clinical center. Investigators and other study staff members should not be able to identify the study assignment until this time. If a randomization assignment is inadvertently disclosed prior to use, the assignment will never be used.

A report of randomization compliance will be generated at the conclusion of the study.

研究类型

介入性

注册 (实际的)

77

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • California
      • Los Angeles、California、美国、90095
        • University of California, Los Angeles
    • Oklahoma
      • Oklahoma City、Oklahoma、美国、73104
        • University of Oklahoma

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 80年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Patients scheduled to undergo coronary artery bypass surgery, major vascular/aneurysm repair requiring bypass, valvular replacement or repair, or both, for clinically indicated reasons.
  2. Age ≥ 18 years.
  3. Sinus rhythm at baseline.
  4. Provision of signed informed consent and stated willingness to comply with all study procedures for duration of the study

Exclusion Criteria:

  1. Emergent surgery
  2. Anticipated amiodarone use
  3. Patients with permanent or persistent atrial fibrillation
  4. Planned concomitant atrial Maze procedure
  5. Complex congenital heart disease
  6. Women who are pregnant (as evidenced by pregnancy test if pre-menopausal).
  7. Left ventricular assist device or status post orthotopic heart or lung transplantation
  8. Unable or unwilling to comply with protocol requirements.
  9. Known channelopathy such as Brugada syndrome, long QT syndrome, or Catecholaminergic monomorphic ventricular tachycardia
  10. Symptomatic sinus bradycardia or sinus node dysfunction at baseline without an implantable pacemaker.
  11. Complete heart block or trifascicular block without an implantable pacemaker
  12. Recurrent vasovagal syncope
  13. Unilateral or bilateral vagotomy
  14. Chronic amiodarone use

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:Intervention Group

Active tVNS (Parasym device, Parasym Health, Inc, London, UK) will be performed with a clip attached to ear at 20 Hz, 250ms at a current just below discomfort threshold for one hour twice a day, starting on post-day 0. Stimulation will continue until 5 days post-operatively or discharge.

20 Hz, 250ms at a current just below discomfort threshold for one hour twice a day, starting on post-day 0. Stimulation will continue until 5 days post-operatively or discharge.

假比较器:Control Group

Sham tVNS will be performed by attaching the Parasym device to the ear and setting output to 0. Stimulation will continue until 5 days post-operatively or discharge.

Current set a 0 mA, starting on post-op day 0. Stimulation will continue until 5 days post-operatively or discharge.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Number of Participants With Atrial Fibrillation
大体时间:6 days

Incidence of post-operative atrial fibrillation for postoperative day 0-5 (postop day 0 is the day of the surgery and is the first day of the time frame and postoperative day 5 is the 6th day).

6 days

次要结果测量

结果测量
措施说明
大体时间
Days of Hospitalization
大体时间:Postop day 0 until discharge from the hospital, an average of 1 week.

Number of days in the hospital from postoperative day 0 to discharge.

Postop day 0 until discharge from the hospital, an average of 1 week.
Inflammatory Markers
大体时间:Within 12 hours of arrival to the ICU after surgery and on postop day 3 (2 days)

Reduction in inflammatory markers including C-reactive protein (CRP), Interleukin 10 (IL-10), Tumour Necrosis Factor alpha (TNF-alpha), Interleukin 6 (IL-6), and Interleukin 1 beta (IL-1β)

Within 12 hours of arrival to the ICU after surgery and on postop day 3 (2 days)
Sympathetic Neural Markers
大体时间:Postop day 3 (1 day)

Reduction in sympathetic neural markers including norepinephrine, Neuropeptide Y (NPY), and galanin.

Postop day 3 (1 day)
Pain Assessment
大体时间:6 days

Pain scores will be assessed on postoperative days 0-5 using the visual analog score (Scale 0-10). Zero for no pain and ten being the worst pain experienced. They will be obtained and recorded into the medical record by the nurse monitoring the subject as part of standard care. Postop day 0 is the day of the surgery and is the first day of the time frame and postoperative day 5 is the 6th day.

6 days
Narcotic Usage
大体时间:6 days

The number of participants in each group that had narcotic usage reported (Y/N) postoperatively. Postop day 0 is the day of the surgery and is the first day of the time frame and postoperative day 5 is the 6th day.

6 days
Duration of Post-op Atrial Fibrillation
大体时间:6 days

How many hours or days for each incidence of postoperative atrial fibrillation for postoperative days 0-5 (postop day 0 is the day of the surgery and is the first day of the time frame and postoperative day 5 is the 6th day).

6 days
Heart Rate During Atrial Fibrillation
大体时间:6 days

The heart rate during each incidence of postoperative atrial fibrillation for postop days 0-5 (postop day 0 is the day of the surgery and is the first day of the time frame and postoperative day 5 is the 6th day).

6 days

其他结果措施

结果测量
措施说明
大体时间
The Number of Participants in Each Group That Had Narcotic Usage Reported (Y) Postoperatively
大体时间:Postoperative days 0-5

We are reporting the number of participants in each group from only 1 site that had narcotic usage reported (binary Y/N) postoperatively.

Postoperative days 0-5

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Stavros Stavrakis, MD, PhD、University of Oklahoma
  • 首席研究员:Jonathan Ho, MD、University of California, Los Angeles
  • 首席研究员:Marmar Vaseghi, MD、University of California, Los Angeles

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年9月20日

初级完成 (实际的)

2024年3月25日

研究完成 (实际的)

2024年4月25日

研究注册日期

首次提交

2020年7月29日

首先提交符合 QC 标准的

2020年8月12日

首次发布 (实际的)

2020年8月17日

研究记录更新

最后更新发布 (实际的)

2026年9月22日

上次提交的符合 QC 标准的更新

2026年8月26日

最后验证

2026年8月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

是的

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅